---
title: "NeuroOne Advances StereoCED Toward Human Clinical Studies"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297210429.md"
description: "NeuroOne Medical Technologies (NMTC) completed three large-animal procedures using its StereoCED platform, validating technical feasibility for human clinical trials later in Q4 2026. The company anticipates revenue from animal research devices in fiscal Q4 2026. While analysts maintain a 'Buy' rating with an $8 target, TipRanks’ AI assigns a 'Neutral' score due to weak financial performance and cash burn despite recent revenue growth."
datetime: "2026-08-27T13:28:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297210429.md)
  - [en](https://longbridge.com/en/news/297210429.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297210429.md)
generator: "portal-rs"
---

# NeuroOne Advances StereoCED Toward Human Clinical Studies

NeuroOne Medical Technologies ( (NMTC) ) has provided an update.

On August 27, 2026, NeuroOne reported the successful completion of three large-animal procedures at the University of Minnesota using its next-generation StereoCED platform for robotic-assisted intracerebral drug delivery and electrophysiological monitoring. In two cases, the company’s drug delivery electrodes both infused a study agent into targeted brain tissue and recorded intracranial activity from the same regions, a combination NeuroOne says is a first in convection-enhanced delivery.

The repeatable results in a large-animal epilepsy research program validated the platform’s technical feasibility and integrated surgical workflow, bolstering NeuroOne’s plans to launch StereoCED for human investigational clinical studies later in the quarter. Development of StereoCED devices for animal use finished ahead of schedule, enabling earlier-than-expected sales, with related revenue from the research program expected to be recognized in fiscal Q4 2026 as human-use devices near release by the end of that quarter.

The most recent analyst rating on (NMTC) stock is a Buy  
 with a $8.00 price target.  
 To see the full list of analyst forecasts on NeuroOne Medical Technologies stock,  
 see the NMTC Stock Forecast page. 

**Spark’s Take on NMTC Stock**

According to Spark, TipRanks’ AI Analyst, NMTC is a Neutral.

The score is held down primarily by weak financial performance—deep operating losses and sizable, worsening cash burn—despite strong recent revenue growth and low leverage. Technicals also reflect a clear downtrend. The earnings call provided some support via reiterated guidance and operational milestones, but near-term liquidity pressure and execution/timing uncertainty keep the overall score below average.

To see Spark’s full report on NMTC stock,  
 click here. 

**More about NeuroOne Medical Technologies**

NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care for patients with neurological disorders. It markets minimally invasive, high-definition electrode platforms, including Evo cortical and sEEG electrodes and OneRF ablation systems for brain and trigeminal nerve, and is pursuing R&D programs in drug delivery, basivertebral nerve ablation and spinal cord stimulation.

**Average Trading Volume:** 50,186

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $19.67M

For a thorough assessment of NMTC stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [NMTC.US](https://longbridge.com/en/quote/NMTC.US.md)

## Related News & Research

- [NeuroOne Medical Chief Business Officer David J. Wambeke acquires 33,333 common shares worth $66,999.33](https://longbridge.com/en/news/298319958.md)
- [NeuroOne reports successful large-animal procedures using next-generation StereoCED platform](https://longbridge.com/en/news/297191400.md)
- [BioNxt starts large-animal pharmacokinetic study of sublingual everolimus film for transplant rejection](https://longbridge.com/en/news/298275245.md)
- [Pharvaris rises on late-stage trial win for hereditary angioedema drug](https://longbridge.com/en/news/298315480.md)
- [Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market | COSM Stock News](https://longbridge.com/en/news/298467257.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**